


Claims

1. A compound of the formula (I)

(I)



wherein

A is CH or nitrogen;

R is hydrogen or halogen or C₁-C₆ straight or branched chain alkyl group;

R¹ is hydrogen or halogen, or

C₁-C₆ straight or branched chain alkyl group, or

C₁-C₆ straight or branched chain alkoxy group, or mono- or polyhalogenated C₁-C₆ straight or branched chain haloalkyl group;

R² is hydrogen or halogen, or

C₁-C₆ straight or branched chain alkyl group, or

C₁-C₆ straight or branched chain alkoxy group, or mono- or polyhalogenated C₁-C₄ straight or branched chain haloalkyl group;

R³ is hydrogen, or

C₁-C₆ straight or branched chain alkyl group, optionally substituted with C₃-C₆ cycloalkyl group, or mono- or polyhalogenated C₁-C₆ straight or branched chain haloalkyl group, or


C₃-C₆ cycloalkyl group, or

(C₁-C₆ straight or branched chain alkyl)-C(O)-group; or salts, geometric isomers, stereoisomers, diastereomers, or hydrates thereof.

2. The compound of claim 1, wherein R³ is:
hydrogen, or
C₁-C₄ straight or branched chain alkyl group, optionally substituted with C₃-C₆ cycloalkyl group, or
C₃-C₆ cycloalkyl group, or
(C₁-C₄ straight or branched chain alkyl)-C(O)-group.
3. The compound of claim 1, wherein R³ is:
hydrogen, or
C₁-C₄ straight or branched chain alkyl group, optionally substituted with C₃-C₄ cycloalkyl group or fluorine, or
C₃-C₄ cycloalkyl group, or
acetyl.
4. The compound of claim 1, wherein R³ is methyl, ethyl, isopropyl, cyclopropylmethyl, cyclobutyl or fluoroethyl.
5. The compound of claim 1, wherein R³ is isopropyl or cyclopropylmethyl.
6. The compound of claim 1, wherein R² is hydrogen, halogen, trifluoromethyl, or C₁-C₃ alkyl group.
7. The compound of claim 1, wherein R² is hydrogen, fluorine, chlorine, or methyl.
8. The compound of claim 1, wherein R² is hydrogen.
9. The compound of claim 1, wherein R¹ is:
hydrogen or halogen, or
C₁-C₄ straight or branched chain alkyl group, optionally mono- or polyhalogenated, or
C₁-C₃ alkoxy group.

10. The compound of claim 1, wherein R¹ is hydrogen, fluorine, chlorine, methoxy, or trifluoromethyl.
11. The compound of claim 1, wherein R¹ is hydrogen, fluorine, or chlorine.
12. The compound of claim 1, wherein R is hydrogen.
13. The compound of claim 1, wherein R is hydrogen and R¹ is chlorine.
14. The compound of claim 1, wherein A is nitrogen.
15. The compound of claim 1, wherein A is CH.
16. The compound of claim 1, selected from the group consisting of:
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{3-methyl-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{3-ethyl-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-fluoro-pyridin-2-yl)methoxy]-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-(benzyloxy)-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(4-fluoro-phenyl)methoxy]-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(4-chloro-phenyl)methoxy]-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(2-fluoro-phenyl)methoxy]-1-{3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 1-[11-chloro-3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-4-[(5-chloro-pyridin-2-yl)methoxy]-1,2-dihydropyridin-2-one;
 4-(benzyloxy)-1-[11-chloro-3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-[3-(cyclopropylmethyl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{3-cyclopropyl-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-{3-cyclobutyl-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl}-1,2-dihydropyridin-2-one;
 4-[(5-chloro-pyridin-2-yl)methoxy]-1-[11-methyl-3-(propan-2-yl)-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-9-yl]-1,2-dihydropyridin-2-one;
 and pharmaceutically acceptable salts thereof.
17. A pharmaceutical composition, comprising a compound of claim 1, and one or more pharmaceutically acceptable excipients, carriers or combination thereof.
18. The pharmaceutical composition of claim 17 for use in the treatment of obesity, obesity related comorbid conditions and complications, diabetes, psychiatric diseases accompanied by weight gain, inflammatory bowel diseases, affective dysfunctions, anxiety disorders, or sleep-wake cycle disorders.
19. Use of the compound of claim 1 in the manufacture of a medicament for the treatment of treating obesity, obesity related comorbid conditions and complications, diabetes, psychiatric diseases accompanied by weight gain, inflammatory bowel diseases, affective dysfunctions, anxiety disorders, or sleep-wake cycle disorders.

20. A compound of formula (II), tert-butyl 9-bromo-1H,2H,3H,4H,5H-[1,4]diazepino[1,7-a]indol-3-carboxylate,



21. The compound of claim 1, in the form of a pharmaceutically acceptable salt.